Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. | MicrobiomeTrials← Back to trialsNCT07616362
Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2029-04
Enrollment target: 110 participants Locations- Hôpital Beaujon, Clichy, France
- Institut Paoli Calmettes, Marseille, France
- Hôpital Lyon Sud, Pierre-Bénite, France
- Hopital Nord Chu Saint Etienne, Saint-Priest-en-Jarez, France
- Hôpital Rangueil, Toulouse, France
Other microbiome trials you might be interested in
Resectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic c…
Seattle, United StatesEst. completion Jul 14, 2027
Pancreatic Ductal Adenocarcinoma
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ab…
Basking Ridge, United StatesEst. completion May 2027